Fluorescent in situ hybridization and real-time quantitative polymerase chain reaction to evaluate HER-2/neu status in breast cancer

4Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background: Breast cancer remains the most common and second lethal cancer in females. HER-2/neu is one of the most important amplified oncogene in breast cancer. The amplification of HER-2 is correlated with decreased survival, metastasis, and early recurrence. The amplification of HER-2/neu gene and synthesis of the protein are reported in 10%-34% of breast cancer cases associated with tumor size, advanced tumor stage, high-grade tumor, young age at diagnosis, absence of steroid hormone receptor, and lymph node involvement. Methods: Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) methods are options to evaluate HER-2 expression. The current study aimed at identifying the correlation between FISH and real-time polymerase chain reaction (PCR) in measuring HER-2 expression. Results: The study investigated the performance of the real-time PCR as measured against FISH method in IHC +2 borderline cases. In a total of 120 IHC 2+ samples, 58.3% were negative and 41.6% positive for HER-2 gene, confirmed by FISH as a gold standard method. The real-time PCR ratio was <1.8 for a majority (82.8%) of the tumor samples with unamplified HER-2 gene by FISH as a gold standard assay. Conclusion: Despite the fact that real-time PCR is a promising method to evaluate HER-2 over expression and a supplementary array to FISH, according to the results of the present study it cannot be utilized instead of gold standard techniques; therefore, additional studies should be carried out to appraise the value of this method to evaluate HER-2 over expression.

Cite

CITATION STYLE

APA

Homaei Shandiz, F., Fani, A., Shakeri, S., Sheikhi, M., Ramezani Farkhani, A., Shajiei, A., & Ayatollahi, H. (2017). Fluorescent in situ hybridization and real-time quantitative polymerase chain reaction to evaluate HER-2/neu status in breast cancer. Iranian Journal of Pathology, 12(1), 67–73. https://doi.org/10.30699/ijp.2017.24228

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free